文献速递神经肿瘤

贝伐珠单抗在恶性胶质瘤患者中引起颅内出血的风险呈剂量依赖性

Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas.
PubMed 文献 · J Neurooncol · 2025-01-02

该单中心回顾性分析纳入2009至2022年接受贝伐珠单抗治疗的173例胶质瘤患者,比较低剂量(<5 mg/kg/周)与常规剂量(5 mg/kg/周)方案的颅内出血累积发生率;常规剂量组全部及症状性颅内出血发生率均更高,多因素Fine-Gray回归显示常规剂量与症状性颅内出血风险增加显著相关(SHR 8.0560;p=0.0442),两组进展后生存无差异。

要点

  • 常规剂量(5 mg/kg/周)贝伐珠单抗组全部颅内出血累积发生率为17.2%,症状性为13.7%。
  • 低剂量(<5 mg/kg/周)组全部颅内出血累积发生率为3.9%,症状性为2.0%。
  • 多因素Fine-Gray回归显示常规剂量与症状性颅内出血风险增加显著相关(SHR 8.0560;p=0.0442)。

核心结论

  • 在該单中心回顾性队列中,常规剂量贝伐珠单抗治疗(5 mg/kg/周)与恶性胶质瘤患者颅内出血发生率增加相关,相比更低剂量(<5 mg/kg/周)。
  • 低剂量与常规剂量组之间未观察到进展后生存差异。

研究设计与样本

  • 单中心回顾性分析,纳入2009年至2022年间因胶质瘤接受贝伐珠单抗治疗的患者。
  • 共173例患者,低剂量组51例,常规剂量组122例。
  • 采用竞争风险分析随时间比较两组颅内出血发生率,并以多因素Cox回归评估进展后生存作为次要结局。

主要发现

  • 全部颅内出血累积发生率常规剂量组为17.2%,低剂量组为3.9%(p=0.0296)。
  • 症状性颅内出血累积发生率常规剂量组为13.7%,低剂量组为2.0%(p=0.0274)。
  • 多因素Fine-Gray回归显示常规剂量贝伐珠单抗治疗与症状性颅内出血风险增加显著相关(SHR 8.0560;p=0.0442)。
  • 低剂量组与常规剂量组之间未观察到进展后生存差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Bevacizumab, an anti-VEGF monoclonal antibody, has become a mainstay therapeutic in the management of malignant glioma. It is unknown if the risk of intracranial hemorrhage (ICH), a major complication associated with bevacizumab use, is dose-dependent. METHODS: This was a single institution retrospective analysis of patients treated with bevacizumab for the management of gliomas between 2009 and 2022. Incidence rates of ICH between patients receiving low-dose (< 5 mg/kg/week) and conventional-dose (5 mg/kg/week) bevacizumab regimens were compared via competing risk analysis over time. We evaluated post-progression survival (PPS) as a secondary outcome using multivariate Cox regression. RESULTS: One hundred and seventy-three patients were identified (low-dose group, n = 51, conventional-dose group, n = 122) for inclusion in our analysis. Cumulative incidence rates of all cases of ICH and clinically symptomatic cases of ICH were higher in the conventional-dose (17.2% for all cases, 13.7% for symptomatic) relative to the low-dose group (3.9% for all cases, 2.0% for symptomatic); p-value 0.0296 for all cases, p-value 0.0274 for symptomatic cases. On multivariate Fine-Gray regression, conventional-dose bevacizumab therapy remained significantly associated with increased risk for symptomatic ICH (SHR 8.0560; p-value 0.0442). No difference in PPS was observed between the low-dose versus conventional-dose groups. CONCLUSIONS: Conventional-dose bevacizumab therapy (5 mg/kg/week) is associated with increased incidence of ICH in patients with malignant glioma compared to lower dose bevacizumab (< 5 mg/kg/week) in this single center retrospective cohort. No difference in PPS was observed between the low-dose versus conventional-dose groups.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Lim S, Clarke NH, Maloney SL, et al. Bevacizumab exerts dose-dependent risk for intracranial hemorrhage in patients with malignant gliomas. J Neurooncol. 2025. PMID: 39747716. doi:10.1007/s11060-024-04916-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。